These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 32006253)

  • 21. TRIM38 suppresses migration, invasion, metastasis, and proliferation in non-small cell lung cancer (NSCLC) via regulating the AMPK/NF-κB/NLRP3 pathway.
    Zhang K; Lin G; Nie Z; Jin S; Bing X; Li Z; Li M
    Mol Cell Biochem; 2024 Aug; 479(8):2069-2079. PubMed ID: 37566200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
    Zhang Y; Zhang Q; Chen H; Wang C
    Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis.
    Ye L; Pu C; Tang J; Wang Y; Wang C; Qiu Z; Xiang T; Zhang Y; Peng W
    Respir Res; 2019 May; 20(1):106. PubMed ID: 31142317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
    IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of PKCζ/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.
    Zhou Q; Dai J; Chen T; Dada LA; Zhang X; Zhang W; DeCamp MM; Winn RA; Sznajder JI; Zhou G
    Cell Signal; 2017 Oct; 38():49-59. PubMed ID: 28652146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
    Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
    Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphine promotes non-small cell lung cancer progression by downregulating E-cadherin via the PI3K/AKT/mTOR pathway.
    Gu F; Zhou Y; Tian L; Chen J; Zhang C; Huang Z; Yu W; Xie K
    Sci Rep; 2024 Sep; 14(1):21130. PubMed ID: 39256509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/Akt Signaling Pathway.
    Wei N; Wu X; Yu Y; Zhou H; Cui K; Zhao X; Zhang X
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):140. PubMed ID: 38682195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling.
    Wu DM; Zhang T; Liu YB; Deng SH; Han R; Liu T; Li J; Xu Y
    Cell Death Dis; 2019 Apr; 10(5):349. PubMed ID: 31024010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
    Xing Y; Meng Q; Chen X; Zhao Y; Liu W; Hu J; Xue F; Wang X; Cai L
    Oncotarget; 2016 May; 7(21):30479-91. PubMed ID: 27058415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway.
    Liang Z; Zhong Y; Meng L; Chen Y; Liu Y; Wu A; Li X; Wang M
    Thorac Cancer; 2020 Nov; 11(11):3155-3167. PubMed ID: 32926529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
    Liu X; Sun L; Zhang S; Zhang S; Li W
    J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT.
    Tang Z; Ding Y; Shen Q; Zhang C; Li J; Nazar M; Wang Y; Zhou X; Huang J
    J Mol Med (Berl); 2019 Jan; 97(1):127-140. PubMed ID: 30478628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
    Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
    Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.